Belimumab treatment in rhupus: A case report with severe skin involvement.

Autor: Castillo Dayer PV; Rheumatology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Lozano Rivas N; Rheumatology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Martínez Ferrín JJ; Rheumatology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Victoria Martínez AM; Dermatology Department, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain., Sánchez-Pedreño Guillen P; Dermatology Department, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain., Marras Fernández-Cid C; Rheumatology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Jazyk: angličtina
Zdroj: Dermatologic therapy [Dermatol Ther] 2019 Sep; Vol. 32 (5), pp. e13056. Date of Electronic Publication: 2019 Aug 20.
DOI: 10.1111/dth.13056
Abstrakt: Patients with rhupus characteristically exhibit symmetric polyarthritis and clinical manifestations suggestive of systemic lupus erythematosus (malar rash, photosensitivity, hematological manifestations, serositis, and/or skin involvement) and positive anti-dsDNA. Treatment is unclear and it can include disease-modifying rheumatic drugs like hydroxyl chloroquine, or methotrexate or, in refractory cases, rituximab or abatacept. We report a case of 31-year-old female who present with rhupus with skin acute lesions treated with belimumab. This is the first case of rhupus treated with this drug described in the literature.
(© 2019 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje